单胎妊娠中全基因组无创产前筛查提示15三体阳性的临床意义及与妊娠结局的关联:前瞻性队列研究、系统综述与Meta分析
该前瞻性队列研究纳入香港单中心36466例单胎妊娠,全基因组NIPS提示15三体阳性者10例(0.027%),阳性预测值40.0%,其中30.0%证实为母源性15号染色体单亲二体。结合29项研究30个队列的Meta分析显示,汇总阳性预测值为17.4%,且阳性者不良妊娠结局发生率68.4%。作者建议对NIPS提示15三体阳性者行羊膜腔穿刺确诊。
要点
- 全基因组NIPS提示15三体阳性时,阳性预测值较低(汇总17.4%),但需警惕母源性UPD15和真性胎儿嵌合体。
- NIPS阳性后羊膜腔穿刺确诊可发现约20.3%的母源性UPD15,胎儿核型正常后UPD15残留风险至少11.3%。
- NIPS阳性者不良妊娠结局发生率68.4%,包括胎儿丢失29.1%、终止妊娠21.5%和妊娠并发症17.7%。
核心结论
- 全基因组NIPS对胎儿15三体的阳性预测值相对较低,但相当比例NIPS阳性病例存在母源性UPD15或胎儿嵌合体,作者强烈推荐对NIPS提示15三体阳性的病例行羊膜腔穿刺以排查UPD15和真性胎儿嵌合体并指导临床管理。
研究设计与样本
- 前瞻性队列研究(香港单中心,2020年1月至2023年4月,36466例单胎妊娠)联合系统综述与随机效应Meta分析(29项研究30个队列,175例NIPS阳性妊娠),以羊膜腔穿刺细胞遗传学和分子分析为参考标准。
诊断标准与关键数值
- 本队列NIPS对15三体的阳性预测值为40.0%(4/10),母源性UPD15为30.0%(3/10);Meta分析汇总15三体发生率为0.013%(95%CI 0.009-0.019%,I²=78.4%),汇总阳性预测值为17.4%(95%CI 4.0-35.0%,I²=51.5%),UPD15阳性率为20.3%(14/69),胎儿15三体或UPD15的汇总阳性预测值为32.6%(95%CI 14.4-53.0%,I²=55.3%),胎儿核型正常后UPD15残留风险至少11.3%。
临床应用与阅片要点
- 作者强烈推荐对任何NIPS提示15三体阳性的病例行羊膜腔穿刺,以排查UPD15和真性胎儿嵌合体并指导后续临床管理;在102例侵入性诊断结果中,22例证实胎儿15三体(8例完全型15三体、14例真性胎儿嵌合体)。
局限性
- 汇总发生率异质性I²=78.4%。
- 汇总阳性预测值异质性I²=51.5%。
- 胎儿15三体或UPD15汇总阳性预测值异质性I²=55.3%。
- UPD15阳性率20.3%的估计假设所有未行UPD15检测的二倍体病例均为正常双亲遗传。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the incidence and clinical significance of a positive result on genome-wide non-invasive prenatal screening (NIPS) for trisomy 15.
METHODS: We conducted a prospective cohort study of singleton pregnancies that underwent genome-wide NIPS at a single center in Hong Kong between January 2020 and April 2023. The incidence of a positive genome-wide NIPS result for trisomy 15, positive predictive value (PPV) for trisomy 15 and risk of uniparental disomy 15 (UPD15) were assessed based on cytogenetic and molecular analyses at amniocentesis. Adverse fetal outcomes were reviewed. Furthermore, a systematic review of cohort studies reporting positive trisomy 15 results from genome-wide NIPS was performed, including data from our prospective cohort. Random-effects meta-analysis was used to obtain pooled estimates of incidence and PPV. The risk of UPD15 and adverse pregnancy outcomes was also evaluated. Heterogeneity was evaluated using Higgins' I2 statistic.
RESULTS: In our cohort of 36 466 singleton pregnancies that underwent genome-wide NIPS, 10 (0.027%) cases were screen-positive for trisomy 15 (2.7 per 10 000 singleton pregnancies). Results from invasive diagnostic testing were available for all screen-positive cases. The PPV of genome-wide NIPS for trisomy 15 was 40.0% (4/10), and 3/10 (30.0%) cases were confirmed to have maternal UPD15. Together with our study, a total of 30 cohorts from 29 studies were included in the systematic review and meta-analysis, comprising 175 pregnancies that were screen-positive for trisomy 15. In 26 cohorts in which the total number of cases screened using NIPS were specified, the pooled incidence of trisomy 15 was 145/1 009 301 (0.013% (95% CI, 0.009-0.019%; I2 = 78.4%)), or 1.3 per 10 000 singleton pregnancies. The pooled incidence was significantly higher among women screened in the first trimester compared with those tested in the second trimester. Among 102 cases with a diagnostic result from invasive testing, 22 were confirmed as having fetal trisomy 15, including eight with full trisomy 15 and 14 with true fetal mosaicism. The pooled PPV for fetal trisomy 15 was 17.4% (95% CI, 4.0-35.0%; I2 = 51.5%). Among 69 cases with a result from UPD15 testing, 14 (20.3%) had maternal UPD15. Assuming that all diploid cases that did not undergo UPD15 testing had normal biparental inheritance of chromosome 15, the pooled PPV for either fetal trisomy 15 or UPD15 was 32.6% (95% CI, 14.4-53.0%; I2 = 55.3%), and the residual risk of UPD15 after a fetal normal karyotype was at least 11.3%. Among patients with clinical follow-up, 68.4% experienced an adverse pregnancy outcome, including fetal loss (29.1%), termination of pregnancy (21.5%) and/or pregnancy complication (17.7%).
CONCLUSIONS: Although the PPV of genome-wide NIPS for fetal trisomy 15 was relatively low, a significant proportion of cases with a positive NIPS result for trisomy 15 had maternal UPD15 or fetal mosaicism, underscoring the need for diagnostic confirmation via amniocentesis. Amniocentesis should be strongly recommended for any case with a positive NIPS result for trisomy 15 to investigate UPD15 and true fetal mosaicism and guide subsequent clinical management. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Xue S, Zheng Y, Cao Y, et al. Clinical significance and association with pregnancy outcome of positive non-invasive prenatal screening for trisomy 15 in singleton pregnancy: prospective cohort study, systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2025. PMID: 41118657. doi:10.1002/uog.70106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。